Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Acquisition Of Cerexa Could Set The Stage For Ceftaroline Launch In 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

The acquisition of the late-stage injectable antibiotic could launch ahead of Orapem.

You may also be interested in...



Actavis Counting On Strong Product Line Depth For Avycaz Launch

The specialty pharma will take advantage of its presence in antibiotics to launch its third FDA-approved antibiotic for hard-to-treat infections before the end of the second quarter.

Optimer Looks To Partner C. Diff Candidate After Trial Success

OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.

Optimer Looks To Partner C. Diff Candidate After Trial Success

OPT-80’s success in the clinic dramatically improves Optimer’s ability to partner the product for a healthy sum.

Related Content

Topics

UsernamePublicRestriction

Register

PS063543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel